Tirzepatide
What this compound does
Tirzepatide (Mounjaro/Zepbound) is a newer FDA-approved injection that hits two gut hormones at once, giving some of the biggest weight-loss results in trials.
- • People with type 2 diabetes
- • Adults with obesity meeting criteria
Weekly injection with slow dose escalation; appetite and weight fall over months. Prescription required.
- • Personal/family history of medullary thyroid carcinoma or MEN2
- • Pregnant people
- • History of pancreatitis (caution)
Manufactured to pharmacopeial standards as a dual-agonist acylated peptide.
How much, when
Peer-reviewed studies
- PMID: 35658024A
Large weight loss
SURMOUNT-1 showed up to ~21% body-weight reduction at the highest dose vs placebo.
- PMID: 34170647A
Superior glycemic control
SURPASS trials showed strong HbA1c reductions, often exceeding GLP-1-only agents.
- PMID 35658024 · 2022rctA
Tirzepatide once weekly for obesity (SURMOUNT-1)
Up to ~21% weight loss
Medicine interactions
- HIGH
Insulin / sulfonylureas· antidiabetic
Additive glucose lowering, hypoglycemia risk.
→ Reduce doses; monitor glucose.
- MODERATE
Oral contraceptives· hormonal
Delayed gastric emptying may reduce absorption after dose escalation.
→ Consider backup contraception per labeling.
This page is a reference summary, not a prescription. Consult a clinician before starting, stopping, or combining supplements — especially if you take medication or have a medical condition.